Articles
E-marketing (part 1)

E-marketing (part 1)

Pharma’s perceived obligation to correct disinformation on their products is fraught with problems in e-marketing. This is why, as Jean Samuel explains, we need to implement policies on how we act in this area, and where we draw the line. Even in the vibrant, constantly changing world of pharma commercial operations, there are aspects where a transition of process from…

Articles
Pharma social media scan: we're not in Kansas anymore

Pharma social media scan: we're not in Kansas anymore

Emma D’Arcy continues her monthly round-up of pharma digital activity with a view this time on regulatory restraints when it comes to social media. March is a busy month in the world of pharmaceutical digital marketing, there are two specialist conferences where you hope to swap ideas, and gain insights and...

Articles
WAIMO: What are IDEAs actually made of?

WAIMO: What are IDEAs actually made of?

In the final piece of his WAIMO series, Mike Rea provides a roundup of the series and asks the ultimate question - what are ideas actually made of? As this series draws to a close, it is interesting to think about what IDEAs are made of (I realise I just made a challengeable assumption there…), but the question any rational reader would pose is...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D